Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS)
NCT02238626 is registered in ClinicalTrials.gov with MediciNova as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS)
- Lead sponsor
- MediciNova
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2014
- Completion date
- December 31, 2017
- Enrollment
- 70 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.